A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?

Slides:

Advertisements

Similar presentations

Should we use bivalirudin ? Fibrin 2 1 Thrombin 2 1 Thrombin 2 1 Trombina 2 1 Trombina Bivalirudin ADVANTAGES - No requirement for anti-thrombin III -

Advertisements

A ggrastat- Phase of the AGGRASTAT to ZOCOR (A to Z) Trial Comparison of the safety and efficacy of unfractionated heparin versus enoxaparin in combination.

Pharmacological strategies to reduce periprocedural bleeding

Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.

Www. Clinical trial results.org Unfractionated heparin 60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50.

Heparin Should be the First-line Therapy for Patients with ACS/AMI

New Horizons for SMA.

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

When Is Adding Aspirin to NOACs Worth the Risk?

Thrombosis, Cancer, and NOACs

Emergency Management of NOAC Bleeding

PAD Patients vs Post-ACS Patients:

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Unmet Needs in the Secondary Prevention in ACS

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Surveying the Safety of NOACs in the Real World

nAMD: Switching Therapies - what you need to know

Tailoring Antiplatelet Therapy in PCI

Antiplatelet Therapy and Secondary Prevention

Anticoagulation Therapy in Patients Post-TAVR

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

Treatment Options to Consider

Are We Closer to Personalized Medicine in MS?

Antithrombotic Protection in CAD and HF

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

A Better Solution For Cancer Patients With VTE?

Drug-Coated Balloons:

Risk Stratification in CAD and PAD

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

% Heparin + GPI IIb/IIIa Bivalirudin +

Duration of Dual Antiplatelet Therapy

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

Cancer-Associated Thrombosis

CAD and HF Often Coexist

Early Management of NSTE-ACS: From the ED to the Cath Lab

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Updates in Anticoagulation: Key Sessions at ESC 2017

PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH

Antithrombotics in Arterial Disease: Focus on Coronary Disease

Program Goals Background: Anticoagulation in Patients With VTE.

Reducing Risk for CV Outcomes

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)

BRIGHT Trial design: Patients undergoing PCI for ACS were randomized in a 1:1:1 fashion to receive either bivalirudin alone, unfractionated heparin (UFH)

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

My PAH Patient.

Top Tips in Evidence-Based Care for HFrEF

Expert Perspectives.

The Power of As-Treated Analyses

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?

Case Scenario

Case Scenario (cont)

ACCOAST Trial Design

Enoxaparin in NSTE-ACS: Synergy Results

Bivalirudin

HORIZONS-AMI Switch 2-Year Outcomes

Fondaparinux*

Otamixaban: In Clinical Development for Management of ACS

Case Scenario (cont)

Case Scenario (cont)

Case Scenario (cont)

Main Limitations of Unfractionated Heparin

ATLAS ACS-2: Primary Efficacy Endpoint

BRIDGE Trial

Summary

Summary (cont)

Abbreviations

Abbreviations (cont)